MetaCap

Foghorn Therapeutics (FHTX) vs Organogenesis (ORGO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Foghorn Therapeutics (FHTX) has outperformed Organogenesis (ORGO) over the past year, losing 62.8% versus a loss of 86.2%. Over five years, FHTX leads with a -87.4% price change compared with -92.2% for ORGO. Foghorn Therapeutics is the larger company by market cap ($103.1 million vs $100.2 million), about 1.0 times the size.

Organogenesis converts more of its revenue into profit, with a net margin of 6.6% versus -240.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FHTX-62.77%ORGO-86.20%
+60%-17%-93%
Nov 21, 20251 yearNov 20, 2026
FHTX-87.43%ORGO-92.22%
+75%-13%-100%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FHTX versus ORGO key metrics
MetricFHTXORGO
Share price$1.72$0.7716
Market cap$103.14M$100.16M
1-day change-3.37%-2.23%
YTD return-68.15%-85.10%
1-year return-62.77%-86.20%
5-year return-87.36%-92.25%
P/E ratio (TTM)19.11—
EPS (TTM)$0.09$-1.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$30.91M$564.17M
Revenue growth (YoY)+36.75%+17.04%
Net income (latest FY)$-74.28M$37.03M
Operating margin-279.49%7.92%
Net margin-240.33%6.56%
52-week high$7.61$5.91
52-week low$1.66$0.73
Distance from 52-week high-77.40%-86.93%
Analyst consensusbuyhold
Avg. price target upside+142.44%—
Average volume843.73K850.26K
Shares outstanding59.96M129.80M
Employees106854
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • FHTX has outperformed ORGO by 23.4 percentage points over the past year.
  • Organogenesis is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -240.3 cents for Foghorn Therapeutics.
  • Foghorn Therapeutics grew revenue faster in its latest fiscal year (+36.75% vs +17.04%).

About Foghorn Therapeutics

FHTX stock →

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees

About Organogenesis

ORGO stock →

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.

Health Care · Biotechnology: Pharmaceutical Preparations · 854 employees

FHTX vs ORGO FAQ

Which is bigger, Foghorn Therapeutics or Organogenesis?

Foghorn Therapeutics (FHTX) is larger, with a market capitalization of $103.14M compared with $100.16M for Organogenesis (ORGO).

Which stock has performed better over the past year, FHTX or ORGO?

FHTX returned -62.77% over the past 12 months, compared with -86.20% for ORGO (price return, excluding dividends). Past performance does not predict future results.

Are Foghorn Therapeutics and Organogenesis in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons